An ophthalmic clinical administration device

By designing the eyelid drive unit and guide component of the ophthalmic clinical drug delivery device, the problems of drug waste and conditioned reflex in traditional eye drop methods are solved, achieving precise, safe, and uniform drug delivery.

CN123058883APending Publication Date: 2026-11-10BEIJING REHABILITATION HOSPITAL CAPITAL MEDICAL UNIVERSITY(BEIJING WORKERS SANATORIUM)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611189062.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-08-06
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Traditional eye drop methods result in significant waste of medication, frequent occurrences of conditioned reflex eye closure, and are difficult to operate precisely, especially for children, the elderly, and patients with hand tremors.

Method used

Design an ophthalmic clinical drug delivery device that drives the patient's eyelids to open and close using an eyelid drive unit, and uses a guide to deliver the drug solution directly to the opening gap through surface tension, achieving precise drug delivery by combining capillary action.

Benefits of technology

It significantly reduces waste of medicine, avoids conditioned reflex eye closing, ensures uniform distribution of medicine, significantly saves medicine usage, and improves the convenience and safety of operation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123058883A_ABST
    Figure CN123058883A_ABST
Patent Text Reader

Abstract

The application discloses an ophthalmic clinical drug delivery device, which comprises a body wearable on a patient's head, a drug delivery module assembled on the body, an eyelid driving unit, a drug supply unit and a controller. The eyelid driving unit drives the upper and lower eyelids to produce opening and closing movement to form an opening gap through a pair of rolling elements. The guide element of the drug supply unit extends towards the opening gap and is separated from the opening gap by a preset interval, which is smaller than the minimum distance required for free dropping of the liquid medicine. The controller controls the drug supply unit to output the liquid medicine when the opening gap is formed, so that the liquid medicine accumulates into droplets at the end of the guide element and contacts the opening gap, and then penetrates into the space between the eyelid and eyeball through surface tension. The application can automatically control the opening and closing of the eyelid and synchronously and accurately deliver the medicine, significantly reduces the waste of the liquid medicine, avoids the conditioned reflex of closing the eyes, promotes the uniform distribution of the liquid medicine by using the massage of the rolling elements and the movement of the eyelid, and improves the drug delivery efficiency and patient comfort.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of ophthalmic therapeutic device technology, specifically relating to an ophthalmic clinical drug delivery device. Background Technology

[0002] Traditional eye drop administration relies on the patient tilting their head back, pulling back their eyelids, and suspending the dropper above the eyeball, allowing the medication to drip freely into the conjunctival sac under gravity. This process has several drawbacks: the drop volume is typically 25-40 μL, while the tear pancreas only holds about 7-10 μL, resulting in significant waste due to overflow; the drop triggers a strong reflexive eye-closing, squeezing out the medication; and patients require training for precise application, especially children, the elderly, and those with hand tremors. Furthermore, while existing eye drop devices have some auxiliary structures, most cannot simultaneously address the issues of medication waste, reflexive eye-closing, and uneven medication distribution. Summary of the Invention

[0003] The technical problem to be solved by the present invention is to provide an ophthalmic clinical drug delivery device that can automatically drive the patient's eyelids to open and close to create an opening gap. At the same time as the opening gap is formed, the drug solution is directly delivered to the opening gap by the guide through the surface tension, thereby greatly reducing drug waste, avoiding conditioned reflex eye closure caused by drug dripping, and using the eyelid opening and closing movement to help distribute the drug solution.

[0004] To address the aforementioned technical problems, the present invention provides an ophthalmic clinical drug delivery device, comprising a body wearable on a patient's head, wherein at least one drug delivery module is mounted on the body, and the drug delivery module includes:

[0005] An eyelid actuation unit includes a pair of rollers configured to contact the patient's upper and lower eyelids respectively and driven to rotate in opposite directions, thereby causing the upper and lower eyelids to open and close, forming an opening gap between them; the width of the opening gap is 0.5-1.0 mm.

[0006] The drug supply unit includes a guide member, the end of which extends toward the opening gap and is spaced apart from the bottom of the opening gap by a preset distance; the preset distance is less than the minimum distance required for the drug liquid to drip freely, so that the drug liquid accumulates into droplets after being output from the end of the guide member, and the droplets contact the opening gap before dripping, so as to directly deliver the drug liquid to the opening gap.

[0007] The controller is used to control the drug delivery unit to output a predetermined amount of drug solution to the guide when the eyelid driving unit forms the opening gap, so that the drug solution penetrates between the eyelid and the eyeball through surface tension when it comes into contact with the opening gap.

[0008] Furthermore, the guide includes a flexible guide bundle extending toward the opening gap, with its end forming the preset distance between it and the opening gap, for guiding the flow of the liquid medicine through capillary action and surface tension.

[0009] Furthermore, the guide also includes a dropper and a rubber sleeve, the rubber sleeve being fitted onto the end of the dropper, and the flexible guide being positioned at the end of the rubber sleeve.

[0010] Furthermore, the drug supply unit also includes a liquid storage chamber and a fluid pump; the controller is configured to control the fluid pump to output a predetermined amount of drug solution to the guide member within each certain number of opening and closing motion cycles.

[0011] Furthermore, each of the rolling elements includes a roller and a soft layer sleeved thereon. The outer surface of the soft layer is provided with a plurality of protrusions, and the diameter of the middle section of the soft layer is smaller than the diameter of its two ends, forming a concave arc-shaped profile to conform to the surface of the eyeball under the eyelid.

[0012] Furthermore, the flexible layer is detachably connected to the roller.

[0013] Furthermore, the device is made of a non-transparent material, and its shell completely covers the patient's eye area; when the patient wears the device, the device completely blocks the patient's vision, making the patient's field of vision dark.

[0014] Furthermore, the drug delivery module is equipped with a sensor for detecting the amount of liquid medicine output by the drug supply unit; the front of the device is equipped with a display screen, and the sensor is electrically connected to the display screen to display the amount of liquid medicine.

[0015] Compared with the prior art, the present invention has the following beneficial effects: 1. Significantly Reduced Medication Usage: Because the preset distance between the guide tip and the opening gap is less than the minimum distance required for the medication to drip freely, the medication does not drip directly under gravity. Instead, it accumulates into droplets until it contacts the eyelid margin, where capillary pressure rapidly draws a small amount of medication (usually less than 5 μL) between the eyelid and the eyeball. Compared to the 25-40 μL usage of traditional eye drops, this saves more than 50% of the medication, reducing treatment costs.

[0016] 2. Avoid conditioned reflex eye closure: The eyelid driving unit continuously drives the upper and lower eyelids to open and close slightly, and the body completely covers the patient's field of vision. The patient cannot focus and see the drug delivery structure, thereby greatly reducing psychological fear and conditioned reflex eye closure, and achieving safe drug delivery.

[0017] 3. Promotes even distribution of medication: The raised strips on the rolling element produce a massage-like effect when applying force to the eyelid, stimulating the meibomian glands and orbicularis oculi muscle; at the same time, the regular opening and closing movements of the eyelids drive the flow of tears on the surface of the eyeball, so that the medication is quickly and evenly distributed on the surface of the eye. Attached Figure Description

[0018] Figure 1 A three-dimensional schematic diagram of an ophthalmic clinical drug delivery device Figure 1 ; Figure 2 A three-dimensional schematic diagram of an ophthalmic clinical drug delivery device Figure 2 ; Figure 3 This is a schematic diagram of the drug delivery module. Figure 4 This is a schematic diagram of the eyelid actuation unit. Figure 5 A three-dimensional schematic diagram of the drug supply unit; Figure 6 A simplified structural diagram of the drug supply unit; Figure 7 A simplified diagram of the structure of a drug delivery device for clinical ophthalmology.

[0019] The numbers in the diagram are as follows: 100. Body; 101. Display / Control Screen; 200. Drug delivery module; 210. Eyelid drive unit; 211. Roller; 212. Roller shaft; 213. Soft layer; 214. Raised strip; 215. Drive gear; 216. Connecting gear; 217. Transmission gear; 218. Motor; 220. Drug dispensing unit; 221. Guide; 222. Soft guide bundle; 223. Dropper; 224. Rubber nozzle; 225. Liquid reservoir; 226. Fluid pump; 230. Sensor; 300. Module rack. Detailed Implementation

[0020] The present invention will now be described in further detail with reference to the accompanying drawings and specific embodiments.

[0021] In the following embodiments, the same or similar reference numerals denote the same or similar elements or elements having the same or similar functions throughout. The embodiments described below with reference to the accompanying drawings are exemplary and are only used to explain the present invention, and should not be construed as limiting the present invention.

[0022] In the description of this invention, it should be understood that terms such as center, longitudinal, transverse, length, width, thickness, upper, lower, front, rear, left, right, vertical, horizontal, top, bottom, inner, outer, clockwise, counterclockwise, etc., indicating orientation or positional relationships, are based on the orientation or positional relationships shown in the accompanying drawings and are only for the convenience of describing and simplifying the description of this invention; therefore, they should not be construed as limiting this invention. Furthermore, terms such as first, second, etc., are used for descriptive purposes only and should not be construed as indicating or implying relative importance or implicitly specifying the number of technical features shown. In the description of this invention, unless otherwise expressly specified and limited, terms such as installation, connection, linking, etc., should be interpreted broadly, and those skilled in the art can understand the specific meaning of the above terms in this application according to the specific circumstances.

[0023] The ophthalmic clinical drug delivery device of the present invention is mainly used in clinical ophthalmic drug delivery scenarios, and is especially suitable for occasions that require precise, small-volume, and contactless drug delivery, such as the treatment of ophthalmic diseases such as dry eye, glaucoma, and keratitis.

[0024] Please see Figures 1 to 7 In one embodiment of the present invention, the device includes a body 100 that can be worn on the patient's head. The body 100 is generally shaped like an eye mask and is made of a non-transparent material. Its shell can completely cover the patient's eye area, so that the patient's vision is completely blocked when wearing the body 100, and the patient is in a dark state, thereby effectively avoiding conditioned reflexes caused by visual stimulation. The body 100 is equipped with at least one drug delivery module 200 (preferably two drug delivery modules 200, corresponding to the left and right eyes respectively). The drug delivery module 200 is mounted on the body 100 via a module frame 300 that can slide back and forth. The sliding module frame 300 can easily adjust the distance and contact pressure between the rolling element 211 and the eyelid to adapt to the facial contours of different patients.

[0025] The module frame 300 is slidably connected to the body 100 via a moving mechanism. The moving mechanism can employ conventional linear drive structures in the art, such as gears and racks, lead screws and nuts, or slider guides. This type of moving mechanism is conventional technology, and those skilled in the art can select appropriate structural forms according to actual needs; therefore, it will not be described in further detail here.

[0026] refer to Figure 3The drug delivery module 200 mainly includes an eyelid driving unit 210 and a drug delivery unit 220. The eyelid driving unit 210 includes a pair of rollers 211, one roller 211 for contacting the patient's upper eyelid and the other roller 211 for contacting the patient's lower eyelid. The two rollers 211 are driven to rotate in opposite directions, thereby causing the upper and lower eyelids to produce regular opening and closing movements, forming an opening gap between the eyelids. This opening gap is temporary and small, its amplitude configured to be insufficient for the patient to form a clear field of vision through the gap sufficient to see the internal structure of the device. Specifically, the width of the opening gap is typically between 0.5-1 mm, and the eyelid movement frequency is greater than 1 Hz, making it impossible for the patient to focus.

[0027] Each rolling element 211 consists of a roller 212 and a soft layer 213 fitted onto it. The outer surface of the soft layer 213 has multiple raised strips 214, which provide a gentle massage effect on the eyelid during rolling, stimulating the meibomian glands and orbicularis oculi muscle, thus helping to improve periocular circulation. The soft layer 213 has an arc-shaped profile along its axial diameter, wider at both ends and narrower in the middle. This biomimetic design allows for better conformity to the surface of the eyeball beneath the eyelid, ensuring stability and comfort in contact between the rolling element 211 and the eyelid. The soft layer 213 is detachably connected to the roller 212, facilitating cleaning, disinfection, or replacement after use.

[0028] In a preferred embodiment, the eyelid driving module employs a gear transmission mechanism to achieve synchronous counter-rotation of the two rolling elements 211. (See reference...) Figure 4 The eyelid driving module includes a motor 218 and a gear set. The gear set consists of a drive gear 215, two connecting gears 216, and at least one transmission gear 217 meshing together. Each rolling element 211 is rotatably mounted on the housing (or fixed bracket) of the drug delivery module 200 via bearings (not shown). The axes of the two rolling elements 211 are parallel to each other and spaced a certain distance apart. The drive gear 215 is fixedly mounted on the output shaft of the motor 218, and the motor 218 inputs torque to the gear set through the drive gear 215. The two connecting gears 216 are coaxially fixedly connected to the corresponding rolling elements 211, such that the first connecting gear 216 drives the first rolling element 211 to rotate, and the second connecting gear 216 drives the second rolling element 211 to rotate.

[0029] A transmission gear 217 is positioned between the drive gear 215 and the two connecting gears 216 to change the direction of rotation and adjust the rotational speed. Specifically, when the drive gear 215 rotates clockwise, the transmission gear 217 reverses the rotation, causing the first connecting gear 216 to rotate counterclockwise and the second connecting gear 216 to rotate clockwise, meaning the two connecting gears 216 rotate in opposite directions. By selecting the gear ratio of the transmission gear 217, the rotational speeds of the two connecting gears 216 and their corresponding rolling elements 211 are ensured to be the same.

[0030] refer to Figure 5 and Figure 6 The drug delivery unit 220 is used to store and deliver the drug solution. The drug delivery unit 220 includes a storage chamber 225, a fluid pump 226, and a guide 221. The storage chamber 225 stores the drug solution to be administered, and the fluid pump 226, under the control of a controller, pumps a precisely measured amount of drug solution to the guide 221. The guide 221 includes a dropper 223, a rubber nozzle 224, and a flexible guide bundle 222. The rubber nozzle 224 is fitted onto the end of the dropper 223, and the flexible guide bundle 222 is further located at the end of the rubber nozzle 224. The flexible guide bundle 222 extends toward the opening gap, maintaining a preset distance between its end and the bottom of the opening gap. This preset distance is designed to be less than the minimum distance required for the drug solution to drip freely under gravity. Therefore, when the drug solution is output from the end of the guide 221, it does not drip immediately but gradually accumulates into droplets at the end. As the droplet increases in volume, its lower end contacts the edge of the opening (i.e., the gap between the eyelid and the eyeball). Due to surface tension and capillary action, the droplet is rapidly drawn into the space between the eyelid and the eyeball upon contact, achieving precise drug delivery without leakage. The entire drug delivery process does not rely on gravity for free fall, and the dosage can be precisely controlled to below 5 μL, which is significantly superior to traditional eye drop methods.

[0031] The flexible guide bundle 222 is made of a flexible material (such as silicone, medical rubber, or elastic fabric). When operational deviations cause the guide 221 to accidentally contact eye tissue, the flexibility of the flexible guide bundle 222 effectively buffers the contact force, preventing damage to the eye. This design further enhances the safety and fault tolerance of the device.

[0032] Furthermore, the specific value of the preset spacing needs to be determined comprehensively based on the surface tension of the liquid medication, the diameter of the end of the guide 221, and the required contact conditions. For example, for eye drops with a surface tension of approximately 43 mN / m, when the outer diameter of the end of the guide 221 is 0.5 mm, the critical diameter for stable droplet suspension is approximately 1.2 mm, and the preset spacing can be set to 0.2-1.0 mm. Within this range, after the liquid medication is output from the end of the guide 221, the droplets formed due to surface tension can contact the edge of the opening gap when their volume is small, thus being drawn in by capillary action. Since the preset spacing is less than the critical diameter for stable droplet suspension, the liquid medication is transferred through contact before reaching the volume required for free dripping under gravity, thereby achieving precise small-dose administration and avoiding the natural dripping of droplets. Those skilled in the art can determine the optimal spacing value through simple experiments based on the actual properties of the liquid medication and the size of the guide 221.

[0033] Furthermore, in the fixed installation method of the drug delivery unit 220, the bottom edge of the drug delivery unit 220 does not extend beyond the bottom of the rolling element 211, to ensure that the guide element 221 and the drug delivery unit 220 thereon do not directly contact the eye tissue during use, thereby avoiding scratches or discomfort to the eye. As an alternative embodiment, the drug delivery unit 220 can adopt a height-adjustable structure design. Specifically, the drug delivery unit 220 is connected to the guide element 221 or the drug delivery module 200 through a sliding mechanism, a threaded adjustment mechanism, or an elastic buckle mechanism, allowing the user to adjust the drug delivery unit 220 to a predetermined height position before use or during operation, according to the individual eyelid thickness or drug delivery location requirements. This predetermined position preferably ensures that the drug outlet of the drug delivery unit 220 is directly facing the target area on the inner or outer surface of the eyelid, and that its bottom end does not extend beyond the bottom of the rolling element 211, so as to achieve safe and accurate drug delivery.

[0034] The device also includes a controller for coordinating the operating timing of the eyelid actuation unit 210 and the medication delivery unit 220. Specifically, the controller controls the fluid pump 226 to output a predetermined amount of medication to the guide 221 within every certain number of opening and closing cycles. For example, medication can be delivered synchronously at the instant the eyelid opens to form an opening gap, so that the droplet contacts and penetrates just when the gap is at its maximum, thereby ensuring effective absorption of the medication and avoiding waste.

[0035] The drug delivery module 200 is also equipped with a sensor 230 to detect the amount of drug output from the drug delivery unit 220, for example, by measuring the drive stroke or flow rate of the fluid pump 226. A display screen 101 is located on the front of the main body 100. The sensor 230 is electrically connected to the display screen 101, enabling real-time display of the current output drug volume information on the display screen 101, facilitating monitoring of the drug delivery process by medical personnel or patients.

[0036] In actual use, the patient first closes their eyes and places the device 100 on their head, with the rolling element 211 positioned against the skin of the upper and lower eyelids. Upon activation, the controller first drives the eyelid drive unit 210, causing the rolling element 211 to rotate and inducing slight opening and closing movements of the eyelids. Because the patient's field of vision is obstructed and the eyelids are in motion, they are unlikely to experience a conditioned reflex of closing their eyes. After a brief adaptation period, the controller, according to a preset program or operating command, activates the drug delivery unit 220 to output the medication as the eyelids open to form an opening gap. The medication penetrates the eye through the contact between the end of the guide element 221 and the opening gap, utilizing surface tension. Subsequently, the eyelids continue to open and close, helping to evenly distribute the medication across the ocular surface. The entire drug delivery process is comfortable and convenient, with high medication utilization.

[0037] The scope of protection of this invention includes, but is not limited to, the above embodiments. The scope of protection of this invention is defined by the claims. Any substitutions, modifications, or improvements to this technology that are easily conceived by those skilled in the art fall within the scope of protection of this invention.

Claims

1. An ophthalmic clinical drug delivery device, comprising a body (100) wearable on a patient's head, characterized in that, The body (100) is equipped with at least one drug delivery module (200), the drug delivery module (200) comprising: The eyelid driving unit (210) includes a pair of rollers (211) which are respectively configured to contact the patient's upper eyelid and lower eyelid and are driven to rotate in opposite directions, thereby causing the upper and lower eyelids to open and close, forming an opening gap between them; the width of the opening gap is 0.5-1.0 mm. The drug supply unit (220) includes a guide (221) with its end extending toward the opening gap and spaced apart from the bottom of the opening gap by a preset distance. The preset distance is less than the minimum distance required for the drug to drip freely, so that the drug accumulates into a droplet after being output from the end of the guide (221), and the droplet contacts the opening gap before dripping, so as to directly deliver the drug to the opening gap. The controller is used to control the drug delivery unit (220) to output a predetermined amount of drug solution to the guide (221) when the eyelid driving unit (210) forms the opening gap, so that the drug solution penetrates between the eyelid and the eyeball through surface tension when it comes into contact with the opening gap.

2. The ophthalmic clinical drug delivery device according to claim 1, characterized in that, The guide (221) includes a soft guide bundle (222) extending toward the opening gap, with its end forming the preset distance with the opening gap, for guiding the flow of the liquid medicine through capillary action and surface tension.

3. The ophthalmic clinical drug delivery device according to claim 2, characterized in that, The guide (221) also includes a dropper (223) and a rubber sleeve (224), the rubber sleeve (224) being fitted onto the end of the dropper (223), and the soft guide bundle (222) being located at the end of the rubber sleeve (224).

4. The ophthalmic clinical drug delivery device according to claim 1, characterized in that, The drug supply unit (220) also includes a liquid storage chamber (225) and a fluid pump (226); the controller is configured to control the fluid pump (226) to output a predetermined amount of drug solution to the guide (221) in every certain number of opening and closing motion cycles.

5. The ophthalmic clinical drug delivery device according to claim 1, characterized in that, Each of the rolling elements (211) includes a roller (212) and a soft layer (213) sleeved thereon. The outer surface of the soft layer (213) is provided with a plurality of protrusions (214), and the diameter of the middle section of the soft layer (213) is smaller than the diameter of its two ends, forming a concave arc-shaped profile to fit the surface of the eyeball under the eyelid.

6. The ophthalmic clinical drug delivery device according to claim 5, characterized in that, The soft layer (213) and the roller (212) are detachably connected.

7. The ophthalmic clinical drug delivery device according to claim 1, characterized in that, The device (100) is made of a non-transparent material, and its shell completely covers the patient's eye area; when the patient wears the device (100), the device (100) completely blocks the patient's field of vision, making the patient's field of vision dark.

8. The ophthalmic clinical drug delivery device according to claim 1, characterized in that, The drug delivery module (200) is equipped with a sensor (230) for detecting the amount of liquid medicine output by the drug supply unit (220); the front of the body (100) is equipped with a display screen (101), and the sensor (230) is electrically connected to the display screen (101) for displaying the amount of liquid medicine.